An international, randomized, double-blind study evaluating the efficacy and safety of fondaparinux versus enoxaparin in the acute treatment of unstable angina/non ST-segment elevation MI acute coronary syndromes.

Trial Profile

An international, randomized, double-blind study evaluating the efficacy and safety of fondaparinux versus enoxaparin in the acute treatment of unstable angina/non ST-segment elevation MI acute coronary syndromes.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2016

At a glance

  • Drugs Enoxaparin sodium; Fondaparinux sodium
  • Indications Acute coronary syndromes; Cardiovascular disorders; Embolism and thrombosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MICHELANGELO; OASIS 5
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 14 Oct 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 14 Oct 2011 Company Sanofi added in associations field as reported by ClinicalTrials.gov.
    • 19 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top